mydicar
Mydicar is a genetically targeted enzyme replacement therapy being studied for use in patients with severe heart failure. It is designed to increase the level of SERCA2a, a sarcoplasmic endoplasmic reticulum calcium (Ca2+) ATPase found in the membrane of the sarcoplasmic reticulum (SR). The SERCA2a gene is delivered to the heart via an adeno-associated viral vector. Using the α-myosin heavy chain gene promoter in the cardiac muscle cells, also called cardiomyocytes, Mydicar is able to direct the gene expression only to the heart muscle. Mydicar is being tested in a phase 2 study, in which has been compared to a placebo in 39 advanced heart failure patients. Thus far, patients treated with Mydicar have shown a 52% reduction in the risk of worsening heart failure compared to patients treated with the placebo. — Wikipedia
Clinical trial activity
3 trials · 24 clinical orgs · 0 marketing orgs
Earliest trial started Mar 1, 2007 (NCT00454818)
Timeline
Indications
Mechanism of action
- Sarcoplasmic/endoplasmic reticulum calcium ATPase 2Supplementation
ATP2A2 supplementation
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02346422 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2015 | Celladon Corporation |
| NCT01966887 | Phase 2 | Dec 1, 2013 | Celladon Corporation, University of Paris |
| NCT00454818 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2007 | Allegiance Health, Case Western Reserve University, Celladon Corporation, Columbia University, Icahn School of Medicine at Mount Sinai, Medical City Children's Hospital, Dallas, Methodist Cancer Center, Houston, Texas, Northwestern University, Oregon Health and Science University, Saint Luke's Health System, San Diego Cardiac Center, St. Louis University, Tennessee Center for Clinical Trials, University of California, San Diego, University of Chicago, University of Cincinnati, University of Florida, University of Medicine and Dentistry of New Jersey, University of Pennsylvania, University of Pittsburgh, University of Rochester, University of Wisconsin, Wake Forest University |